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Cardiovascular Features of Heart Failure
With Preserved Ejection Fraction Versus
Nonfailing Hypertensive Left Ventricular
Hypertrophy in the Urban Baltimore Community
The Role of Atrial Remodeling/Dysfunction
Vojtech Melenovsky, MD,*†§ Barry A. Borlaug, MD,* Boaz Rosen, MD,* Ilan Hay, MD,*
Luigi Ferruci, MD, PHD,‡ Christopher H. Morell, PHD,§ Edward G. Lakatta, MD,†
Samer S. Najjar, MD,† David A. Kass, MD*
Baltimore, Maryland
Objectives The purpose of this study was to identify cardiovascular features of patients with heart failure with preserved
ejection fraction (HFpEF) that differ from those in individuals with hypertensive left ventricular hypertrophy
(HLVH) of similar age, gender, and racial background but without failure.
Background Heart failure with preserved ejection fraction often develops in HLVH patients and involves multiple abnormali-
ties. Clarification of changes most specific to HFpEF may help elucidate underlying pathophysiology.
Methods A cross-sectional study comparing HFpEF patients (n  37), HLVH subjects without HF (n  40), and normoten-
sive control subjects without LVH (n  56). All subjects had an EF of 50%, sinus rhythm, and insignificant val-
vular or active ischemic disease, and groups were matched for age, gender, and ethnicity. Comprehensive echo-
Doppler and pressure analysis was performed.
Results The HFpEF patients were predominantly African-American women with hypertension, LVH, and obesity. They had vas-
cular and systolic-ventricular stiffening and abnormal diastolic function compared with the control subjects. However,
most of these parameters either individually or combined were similarly abnormal in the HLVH group and poorly dis-
tinguished between these groups. The HFpEF group had quantitatively greater concentric LVH and estimated mean
pulmonary artery wedge pressure (20 mm Hg vs. 16 mm Hg) and shorter isovolumic relaxation time than the HLVH
group. They also had left atrial dilation/dysfunction unlike in HLVH and greater total epicardial volume. The product of
LV mass index and maximal left atrial (LA) volume best identified HFpEF patients (84% sensitivity, 82% specificity).
Conclusions In an urban, principally African American, cohort, HFpEF patients share many abnormalities of systolic, diastolic,
and vascular function with nonfailing HLVH subjects but display accentuated LVH and LA dilation/failure. These
latter factors may help clarify pathophysiology and define an important HFpEF population for clinical
trials. (J Am Coll Cardiol 2007;49:198–207) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.050h
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(early one-half of patients with heart failure have an ejec-
ion fraction (EF) at or above 50% (1). Despite the high
revalence, morbidity, and economic burden (2–4) of heart
ailure with preserved ejection fraction (HFpEF), its patho-
hysiology remains somewhat controversial and evidence-
ased guidelines for management are lacking. A majority of
FpEF patients are elderly women with a history of systolic
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1,5–9). These are common features in the general popula-
ion, and frequent among African-American women, who
ave the highest prevalence of hypertension worldwide (10).
ost are without heart failure (HF) symptoms, and al-
hough they may have preclinical disease (11) only a
ubgroup develops clinical HFpEF.
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January 16, 2007:198–207 Pathophysiology of Heart Failure With Normal EFCardiovascular features that might best distinguish pa-
ients with HF symptoms from those with similar clinical
eatures such as hypertensive left ventricular hypertrophy
HLVH) but without HF remain unknown, because most
tudies have contrasted HFpEF patients to healthy normo-
ensive (non-LVH) control subjects. Abnormal diastolic
unction (2,12–16), vascular stiffening (17–19), and in-
reased ventricular end-systolic stiffness (elastance [18])
ave all been implicated, but it is unclear which descriptors
re most specific and independent. Accordingly, the goal of
he present study was to comprehensively assess resting
entricular and vascular physiologic properties in an inner-
ity cohort of HFpEF patients, and compare the findings
ith those obtained in 2 control groups with similar mean
ge, race, and gender with or without chronic HLVH. We
ypothesized that many ventricular and arterial abnormalities
hought to underlie HFpEF would be shared by asymptomatic
LVH subjects, but that other changes would be observed
ore selectively in HFpEF that might highlight critical mal-
daptations and/or novel pathophysiology.
ethods
tudy subjects. The HFpEF patients were prospectively
dentified from admission records at Johns Hopkins Hos-
itals between January 2002 and June 2005. Heart failure
as rigorously defined by Framingham criteria (see the
ppendix for supplemental Table A) (20–22) and indepen-
ently adjudicated by 2 cardiologists. All HFpEF subjects
ad been hospitalized for pulmonary congestion diagnosed
y chest radiogram and clinical examination, had EF 50%
ithin 24 to 72 h of index admission, and were required to
e in sinus rhythm. There were no other a priori inclusion
riteria. Patients with active ischemic heart disease (i.e.,
ngina, positive stress test, acute coronary syndrome), seg-
ental wall motion abnormalities, atrial flutter/fibrillation,
alvular disease (more than trace regurgitation or stenosis),
rimary hypertrophic or other cardiomyopathy (e.g., amyloid),
ericardial disease, anemia (hemoglobin 10 g/dl), hyperthy-
oidism, renal failure (creatinine 3 mg/dl or requiring
ialysis), advanced pulmonary disease or pulmonary hyper-
ension (estimated pulmonary artery systolic 60 mm Hg),
r cognitive impairment precluding participation were
xcluded.
Two control groups were studied. The HLVH subjects
ere identified from outpatient echocardiogram records and
creened using hospital records, interview, and formal his-
ory and physical to confirm lack of diagnosis, treatment, or
ymptoms for clinical HF. The other group was made up of
ormotensive subjects without LVH, recruited from partic-
pants in the Baltimore Longitudinal Study of Aging (8).
he latter were asymptomatic and had no prior diagnosis,
istory, or hospitalization for HF or cardiovascular disease
except for mild and well controlled hypertension in some).
oth control groups were selected from a larger screening
ool so that the predominant ethnicity (African American), (ender (female), and age (50
ears) matched the mean values
or the HFpEF group. Identical
xclusion criteria used for HFpEF
atients applied to the control
roups. The study was designed as
rospective. Owing to application
f selection criteria, studied sub-
ects were nonconsecutive. The
rotocol was approved by the
ohns Hopkins Medical Institu-
ions and National Institute on
ging Institutional Review Board,
nd written informed consent was
btained.
tudy procedures. Clinical
ymptoms were assessed in the
FpEF and HLVH groups by
he Minnesota Living with Heart Failure Questionnaire
MLHFQ). All subjects were studied in a stable compen-
ated state (1 month after discharge from an HF hospi-
alization for HFpEF). Measurements were made after15
in rest in a supine position and involved comprehensive
cho-Doppler (Sonos 5500, Philips, Andover, Massachu-
etts), pulse tonometry (VP2000, Omron Healthcare Inc.,
annockburn, Illinois), and arm-cuff (Dinamap, Tampa,
lorida) pressure measurements. Reserve function to acute
fterload increase (sustained isometric handgrip, 30% of
aximal) was tested in the HFpEF and HLVH groups,
ecording blood pressure and cardiac echo-Doppler images.
ardiac function analysis. Echo-Doppler images were
nalyzed off line by a single investigator blinded to subject
roup. Stroke volume (SV) was determined as LV outflow-
ract area  flow velocity time integral by pulsed Doppler
23). Ejection fraction was calculated from parasternal
ong-axis views using the Teichholz formula. The LV
nd-diastolic volume (EDV) was equal to SV/EF (24). The
V mass (25) was indexed to body height (LVMI 
/m2.7), and LVH was defined using gender-specific thresh-
lds (26). Geometry was indexed by relative wall thickness
LV septum  posterior wall thickness)/LV internal diam-
ter) and LVM/EDV. Total epicardial volume was calcu-
ated from 2 hemiellipsoids containing both atria or ventri-
les using an apical 4-chamber view.
Systolic function included EF, endocardial and midwall
ractional shortening (mFS) (27), ratio of observed (o) to
redicted (p) mFS (o/pmFS, a contractility index [12];
mFS 29.08 0.0006 circumferential wall stress [28]),
nd peak systolic chamber elastance (Ees) (29). Diastolic
unction was assessed by peak early (E) and late (A) mitral
oppler flow velocity, deceleration time, isovolumic relax-
tion time, pulmonary venous systolic/diastolic velocity ratio
pvS/D), longitudinal early (E=) and late (A=) tissue velocity
pulsed Doppler) at both mitral annular insertions, and
veraged data. Mean pulmonary artery wedge pressure
Abbreviations
and Acronyms
Ea  arterial elastance
Ees  end-systolic
elastance
HF  heart failure
HFpEF  heart failure with
preserved ejection fraction
HLVH  hypertensive left
ventricular hypertrophy
LA  left atrial
LV  left ventricular
LVH  left ventricular
hypertrophy
PAWP  pulmonary artery
wedge pressurePAWP) was estimated by E/E= (30–32). Diastolic dys-
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Pathophysiology of Heart Failure With Normal EF January 16, 2007:198–207unction was graded according to mitral, pulmonary vein
ow and myocardial tissue Doppler profiles using a modi-
ed scale (see the Appendix for supplemental Table B) (33).
eft atrial (LA) volumes were calculated by area-length
ethod from apical 4-chamber views (34) to measure
aximal, minimal, and diastasis LA volumes (LAVmax,
AVmin, and LAVdiastasis) and active and passive emptying
unction. In a subset of patients (HFpEF, n  21; HLVH,
 25), tissue-Doppler images were obtained in color-code
ode from the apical 4-chamber view (Vivid7, GE Health-
are, Chalfont St. Giles, United Kingdom) at rest and at
eak of a 6-min sustained handgrip exercise to assess atrial
nd cardiac reserve.
rterial function. Arterial function was assessed by ca-
otid artery applanation tonometry (35) and oscillometric
rachial pressure. Carotid systolic pressure augmentation
augmentation index) was calculated from digitalized (1.2
Hz) waveforms by standard algorithm, and waveforms
ere calibrated to match brachial mean and diastolic
lood pressure (35). Total arterial compliance was esti-
ated by SV/carotid pulse pressure ratio (36), and
ffective arterial elastance (Ea), a measure of total LV
fterload, was estimated by the LV end-systolic pres-
ure/SV ratio (37).
tatistical analysis. Data are reported as mean  SD,
nd p values are 2-sided with p  0.05 considered to be
ignificant. Between-group differences were assessed by
-way analysis of variance with a post hoc Bonferroni test
or 3 comparisons, and categorical variables were assessed
y chi-square test (version 12.0, SPSS Inc., Chicago,
llinois). Correlations were tested by the Pearson coeffi-
linical Characteristics
Table 1 Clinical Characteristics
Controls (n  56) H
Age‡, yrs 65 11
Female gender‡, % 70
African-American race‡, % 61
NYHA functional class 1.2 0.4
MLHFQ score np
Height, cm 168 8
Weight, kg 78 18
Body mass index‡, kg/m2 28 5
Body surface area‡, m2 1.9 0.2
Serum creatinine‡, mg/dl1 1.0 0.5
Hemoglobin concentration‡, g/dl1 13.4 1.4
Comorbidity, %
Hypertension‡ 34
Diabetes mellitus‡ 3
Coronary artery disease‡ 2
Left ventricular hypertrophy 0
Medication, %
Diuretics loop/non-loop 0/21
Calcium blocker‡/beta-blocker‡ 9/11
ACEI‡/ARB/aldosterone antagonist 9/4/2
p  0.05 versus HLVH group; †p  0.05 versus control group; Bonferroni post hoc test or chi-sq
ACEI  angiotensin-converting enzyme inhibitors; ARB  angiotensin receptor blockers; HFpEF  hea
LHFQ  Minnesota Living with Heart Failure Questionnaire; np  not performed; NYHA  New York Heient. Between-group differences were further evaluated
y analysis of covariance to adjust for effects of specific
ovariates.
To identify variables that best identified HFpEF from
LVH groups, linear discriminant analysis with back-
ard elimination was used to generate a linear predictor
unction that provided the best between-group discrim-
nation (version 9.1.2, SAS Institute, Cary, North Caro-
ina). Remaining variables were entered into a classifica-
ion/regression tree analysis (CART) yielding binary
plits at optimal values according to the largest improve-
ent of goodness of the fit (S-PLUS 7.0, Insightful,
eattle, Washington).
esults
emographics and comorbidities. The HFpEF patients
ere predominantly older African-American (76%)
omen (84%). While not required for inclusion, all
FpEF patients had hypertension and ventricular hyper-
rophy, and most were obese (body mass index [BMI]
30 kg/m2 in 86%) (Table 1). The HFpEF patients had
higher prevalence of noninsulin-dependent diabetes
61%), coronary artery disease (CAD) history (42%),
nemia, and mild renal dysfunction, consistent with
arlier reports (5). The HFpEF patients were symptom-
tic, with a mean quality of life (QOL) score similar to
hat of severe systolic failure. The HLVH subjects were
ess obese (BMI 30 kg/m2 in 50%), less treated with
iuretics, beta-blockers, and angiotensin-converting en-
yme inhibitors (ACEI), and had a QOL score in the low
n  37) HLVH Without HF (n  40) p Value
10 67 10 0.61
4 78 0.28
6 73 0.25
0.5*† 1.4 0.5 0.01
34* 10 12 0.01
10† 164 9 0.02
24*† 84 17 0.01
8*† 31 6† 0.01
0.3*† 2.0 0.2 0.01
0.7*† 1.0 0.3 0.01
1.3*† 12.8 1.5 0.01
0† 93† 0.01
1*† 35† 0.01
2*† 10 0.01
0† 90† 0.01
20* 10/45 0.01/0.02
81*† 35/43† 0.01/0.01
14/5 30†/30†/9 0.01/0.01/0.40
categorical variables; ‡variables used in discriminant analysis.FpEF (
65
8
7
2.6
50
162
99
37
2.1
1.4
11.6
10
6
4
10
87*/
57/
68*†/
uare for
rt failure with preserved ejection fraction; HLVH  hypertension and left ventricular hypertrophy;
art Association.
t
w
H
s
2
h
B
a
c
c
C
s
A
c
t
L
t
t
i
m
v
s
t
v
w
s
t
H
u
c
e
a
D
s
j
a
d
e
m
t
a
0
s
h
c
s
t
C
* es used
L
*
201JACC Vol. 49, No. 2, 2007 Melenovsky et al.
January 16, 2007:198–207 Pathophysiology of Heart Failure With Normal EFo normal range. The control subjects had a prevalence of
ell controlled HTN typical for their age.
emodynamics and vascular properties. Heart rate and
troke volume were nearly identical among groups (Table
). The latter remained so after indexing to either body
eight or body surface area (BSA) (p  0.5 and 0.3).
rachial and carotid pressures, total arterial resistance (raw
nd BSA indexed), and Ea were greater in HFpEF than in
ontrol subjects, and total arterial compliance was reduced—all
onsistent with arterial stiffening and systolic hypertension.
ardiac output was similar, although cardiac index was
lightly lower in HFpEF than in control subjects (see the
ppendix for supplemental Table C). Nearly identical
hanges were observed in HLVH, suggesting they were due
o coexisting clinical features and not specific to HFpEF.
eft ventricular structure and systolic function. Ven-
ricular hypertrophy was quantitatively greater in HFpEF
han in HLVH whether expressed as absolute mass or
ndexed to body height, BSA (see the Appendix for supple-
ental Table C), or height2.7 (Table 3). LV end-diastolic
olume was similar among groups (Table 3) and remained
o after normalizing to body height, height2.7, or BSA (see
he Appendix for supplemental Table C). The LV mass/
olume or wall thickness/dimension concentricity indexes
entral and Peripheral Hemodynamic Parameters
Table 2 Central and Peripheral Hemodynamic Parameters
Controls (n  56)
Heart rate‡, min1 65 8
Stroke volume, ml 81 21
Brachial systolic‡ and diastolic‡ BP, mm Hg 118 15/65 10
Cardiac output‡, l/min1 5.0 0.88
Total arterial resistance‡, dynes·s/cm5 1,345 262
Carotid mean BP, mm Hg 83 14
Carotid pulse BP, mm Hg 39 9
Carotid augmentation index‡, % 17 16
Total arterial compliance, ml/mm Hg1 2.08 0.6
Arterial elastance‡, mm Hg/ml1 1.40 0.2
p  0.05 versus HLVH group; †p  0.05 versus control group; Bonferroni post hoc test; ‡variabl
BP  blood pressure; other abbreviations as in Table 1.
eft Ventricular Structure and Systolic Function
Table 3 Left Ventricular Structure and Systolic Function
Controls (n  56)
LV mass‡, g·m2.7 36 7
LV relative wall thickness‡ 0.48 0.09
LV ED wall thickness, mm 10 1.5/10 1.2
LV ED diameter, mm 42 5
LV ED volume‡, ml 111 24
LV ejection fraction‡, % 72 10
Endocardial fractional shortening, % 41 8
Circumferential ES stress, kdyne/cm2 120 34
Midwall fractional shortening, % 22 6
Observed/predicted midwall FS‡, % 98 28
LV ES elastance‡, mm Hg/ml1 2.73 0.7
Systolic annular tissue velocity (Sm), cm/s‡ 8.3 1.7p  0.05 versus HLVH group; †p  0.05 versus control group; Bonferroni post hoc test; ‡variables used
ED  end-diastolic; ES  end-systolic; FS  fractional shortening; LV  left ventricular; other abbreviaere highest in HFpEF (Table 3, see the Appendix for
upplemental Table C). The EF was near-identical, whereas
he mitral-annular systolic velocity was slightly lower in
FpEF and HLVH, consistent with LVH. Peak ventric-
lar systolic stiffness (Ees) was higher in HFpEF than in
ontrol subjects, as previously reported (18), but similarly
levated in HLVH subjects. This change remained after
djusting for medication use.
iastolic ventricular function. The HFpEF patients had
everal diastolic abnormalities compared with control sub-
ects (Table 4); however, once again, many were similarly
ltered in non-HF HLVH subjects. Only 2 parameters
iffered between HFpEF and HLVH. The E/E= ratio, an
stimate of PAWP, was somewhat higher in HFpEF, with
ore patients exceeding 18 mm Hg in HFpEF (57.1%)
han in HLVH (31.6%) (p  0.03). This disparity persisted
fter adjusting for LVMI or BSA (p  0.024 and p 
.001, respectively). Isovolumic relaxation time (IVRT) was
horter in HFpEF than in HLVH, which could relate to a
igher PAWP, although the variables were not significantly
orrelated (p  0.27).
Figure 1 shows diastolic dysfunction grades, revealing
ubstantial overlap in HFpEF and HLVH subjects. Al-
hough 59.4% of HFpEF patients had mild to moderate
FpEF (n  37) HLVH Without HF (n  40) p Value
63 11 64 11 0.63
77 17 77 11 0.56
 25†/69 14 145 23†/74 12† 0.01/0.01
5.0 1.1 4.9 1.3 0.87
,558 397*† 1,707 532† 0.01
97 16† 103 19† 0.01
62 18† 55 13† 0.01
23 11 26 15† 0.01
1.36 0.5† 1.52 0.6† 0.01
1.67 0.5† 1.78 0.5† 0.01
in discriminant analysis.
HFpEF (n  37) HLVH Without HF (n  40) p Value
81 23*† 58 12† 0.01
0.68 0.14*† 0.60 0.10† 0.01
 2.6*†/15 2.6*† 14 1.7†/13 1.7† 0.01
45 5† 43 4 0.01
115 33 112 32 0.54
72 11 72 10 0.98
42 10 41 8 0.80
106 40 120 35 0.15
19 6 19 6 0.053
85 24 85 28 0.025
3.51 1.8† 3.72 1.4† 0.01
6.4 1.4† 7.2 1.4† 0.01H
143
116in discriminant analysis. Sm was averaged from septal and lateral part of mitral annulus.
tions as in Table 1.
d
H
I
o
0
d
c
A
w
m
6
g
w
a
0
n
u
t
p
a
s
v
p
a
r
t
m
l
A
i
s
t
h
(
1
c
r
a
L
*
o
pulmon
202 Melenovsky et al. JACC Vol. 49, No. 2, 2007
Pathophysiology of Heart Failure With Normal EF January 16, 2007:198–207ysfunction (grades I and II), this also applied to 67.5% of
LVH subjects (p  0.4). Advanced dysfunction (grade
II) was rare in both groups (p  0.26), and no dysfunction
ccurred in 16.2% of HFpEF versus 30% of HLVH (p 
.15). Even 35.7% of the control subjects displayed some
ysfunction (p  0.001). Remaining subjects were not
lassifiable by this scheme.
trial volumes and function. Left atrial size and function
ere similar in the HLVH and control subjects but abnor-
al in the HFpEF subjects (Table 4). The LAVmax was
8% higher in HFpEF than in control subjects and 40%
eft Ventricular Diastolic Function and Left Atrial Morphology and F
Table 4 Left Ventricular Diastolic Function and Left Atrial Morp
Controls (n  56)
Mitral flow
E‡ and A velocity, cm/s 80 16/78 20
E/A ratio‡ 1.1 0.3
E–deceleration time‡, ms 219 42
Isovolumic relaxation time‡, ms 78 11
Pulmonary vein S/D velocity ratio‡ 1.5 0.9
Diastolic annular tissue velocities
E=‡, cm/s 9.8 2.3
A=‡, cm/s 9.3 2.1
E/E= ratio‡ 8.4 2.2
PAWP estimate (from E/E=), mm Hg 12 2.7
Diastolic dysfunction grade‡, 0–3 0.6 0.9
LA volume
Maximal‡, ml 50 13
Diastasis, ml 32 11
Minimal, ml 19 8
LA emptying fraction
Total‡, % 63 12
Passive, % 36 11
Active, % 42 13
Maximal LA volume  LV mass/height2.7, ml·g/m2.7 1,850 862
p  0.05 versus HLVH group; †p  0.05 versus control group; Bonferroni post hoc test; ‡variable
f mitral annulus.
A=  late diastolic tissue velocity; E=  early diastolic tissue velocity; LA  left atrial; PAWP 
Figure 1 The Prevalence of DD Grades in Each Subject Group
Patients unclassifiable by the scheme are noted as indeterminate. There was
substantial overlap in the prevalence of diastolic dysfunction (DD) in symptom-
atic heart failure with preserved ejection fraction (HFpEF) and asymptomatic
hypertensive left ventricular hypertrophy (HLVH) subjects.(reater than in HLVH (both p 0.0001). These disparities
ere preserved after indexing to BSA or by multivariate
djustment to BSA, LV mass, and estimated PAWP (p 
.007) (Fig. 2). Therefore, differences in LA volume were
ot related to resting high filling pressures, altered ventric-
lar geometry, or differences in anthropometry, although
hey could still have related to differential elevation of LA
ressures during exercise. The LA volume before and after
trial contraction showed similar disparities. Atrial total, pas-
ive, and active emptying fraction was reduced in HFpEF
ersus control or HLVH subjects. The LAVmax was best
redicted by the combination of LVMI, BSA, E/E=, and
ge (z-standardized  coefficients 0.34, 0.26, 0.24, and 0.15,
espectively, by multiple regression with backward elimina-
ion; final r2  0.41).
The combination of biatrial and right ventricular enlarge-
ent, ventricular hypertrophy, and normal LV cavity size
ed to greater total heart (epicardial) volumes (Fig. 3, see the
ppendix for supplemental Table C). This is potentially
mportant, because this volume relates to pericardial con-
traint and right-left heart interaction and could contribute
o higher LV diastolic pressures.
Atrial reserve was assessed during sustained isometric
andgrip in HFpEF and HLVH groups. The increases
percentage change from baseline) of heart rate (8% vs.
1% for HFpEF and HLVH, respectively; p  0.2),
ardiac output (12% vs. 15%; p  0.8), and total arterial
esistance (12% vs. 15%, p  0.9) were similar. However,
rterial pressure response was diminished in HFpEF
ion
y and Function
HFpEF (n  37) HLVH Without HF (n  40) p Value
86 27/92 25† 79 18/93 21† 0.05/0.01
1.0 0.4 0.9 0.3† 0.02
257 112† 247 64 0.03
85 22* 96 17† 0.01
1.2 0.4 1.5 0.3 0.04
6.6 2.4† 7.6 2.7† 0.01
8.1 3.2 9.4 1.9 0.07
15 5.3*† 11 4.5† 0.01
20 6.5*† 1.6 5.6† 0.01
1.4 0.9† 1.1 0.9† 0.01
84 26*† 60 16 0.01
61 23*† 39 14 0.01
42 18*† 24 10 0.01
51 11*† 61 10 0.01
28 12*† 34 11 0.01
32 11*† 40 12 0.01
6,988 2,974*† 3,516 1,367† 0.01
in discriminant analysis. Annular tissue velocities were averaged from the septal and lateral parts
ary artery wedge pressure; other abbreviations as in Table 1.unct
holog
s usedsystolic: 18% vs. 25%, p  0.02; diastolic: 22% vs. 33%,
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nd-diastolic volume, Ees, or systolic and early-diastolic
issue velocities. However, late-diastolic annular tissue
elocity (A=) rose in HLVH subjects but was unchanged
n HFpEF ( 34.9% vs.  5.1%; p  0.004) (Fig. 4),
upporting reduced active atrial contractile reserve in the
F group.
hat parameters best differentiate HFpEF from HLVH
ubjects? Discriminate function analysis was performed to
etermine which parameter set best separated HFpEF from
LVH subjects. Thirty-nine variables (indicated by ‡ in
ables, all reflecting parameters with significant differences
etween groups but avoiding colinearity) were entered, and
remained (misclassification error rate 0.145). These were
in order of influence): LVMI, history of CAD, LAVmax,
Figure 2 Comparison of LA Volumes and Emptying Fractions Ad
Surface Area and Estimated Pulmonary Artery Wedge
Plots show the adjusted mean and 95% confidence interval. HFpEF subjects had s
LA  left atrial; LV  left ventricular; other abbreviations as in Figure 1.
Figure 3 Total Epicardial Versus Left Ventricular
End-Diastolic Chamber Volumes
Increase in total (epicardial) heart volume with similar end-diastolic volume (EDV)
in HFpEF versus HLVH, and both versus control subjects. *p  0.01 versus HLVH;
†p  0.001 versus control subjects. Abbreviations as in Figure 1.elative wall thickness, diastolic blood pressure, history of
AD, total LA emptying fraction , Ees, and ACEI therapy.
nterestingly, no resting vascular or conventional LV dia-
tolic or systolic parameter (including diastolic dysfunction
rade and tissue Doppler-derived indices) remained. Anal-
sis of the remaining variables by CART-derived binary
lassification yielded LVMI (71 g/m2.7) as the major
redictor for HFpEF. A smaller mass but history of CAD
nd LAVmax 83 ml also predicted HFpEF, with a
isclassification rate of 0.148.
The discriminatory capacity of individual parameters was
urther examined by histograms and receiver-operating
urves (ROC). Distributions for E/E= ratio and diastolic
ysfunction grade (Fig. 5A) revealed substantial overlap
d for LV Mass Body
sure for Each Subject Group
ntly greater atrial size and reduced function. *p  0.05 HFpEF versus LVH.
Figure 4 Reduced Atrial Systolic Reserve in HFpEF Patients
The effect of isometric handgrip exercise on late diastolic (A=) annular tissue
velocity in patients with HFpEF (n  21) and asymptomatic HLVH subjects (n 
25). Unlike HLVH subjects, HFpEF patients had minimal increases in A= with
handgrip-exercise. Data shown are mean  SEM. *Between group ANOVA.
Abbreviations as in Figure 1.juste
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VMI and LAVmax (Fig. 5B) had greater separation. The
VMI and LAVmax were only weakly correlated (Fig 5C);
herefore, their product (LVMI  LA-Volmax)—a marker
f combined LV and LA morphologic change—provided
he best discrimination (Figs. 5D and 5E) with an area
nder the ROC of 0.85. An optimal cut-off value of
,418 ml·g/m2.7 separated both groups, with a sensitivity
Figure 5 LV Mass and Atrial Volumes Better Distinguish HFpEF
Histograms for group distributions of E/E= ratio and diastolic dysfunction (DD) grad
and HLVH subjects. (C) LA enlargement was weakly correlated to LVMI, particularl
among study groups. (E) Receiver-operating curves for discriminating between HFp
0.85), followed by LVMI (AUC  0.79) and LAVmax (AUC  0.77). E/E= ratio (AUC
value (4,418 ml  g/m2.7) of LVMI  LAVmax (arrow) separated the groups with a
stolic tissue velocity; E=  longitudinal early tissue velocity; LAV  left atrial volumf 83.8% and a specificity of 82.5%. siscussion
he present study provides the first comprehensive compar-
son between cardiovascular function in HFpEF subjects
nd individuals with hypertension and LVH without symp-
oms, diagnosis, or treatment history of HF. We further
atched age, gender, and ethnicity and included a third
roup without HLVH. Multiple ventricular systolic, dia-
HLVH Subjects Than Indexes of Diastolic Dysfunction
versus LVMI and LAVmax (B). The latter show better separation between HFpEF
e HFpEF subjects. (D) Product of LVMI and LAVmax provides the best separation
HLVH. The most optimal characteristic was found for LVMI  LAVmax (AUC 
) and DD grade (AUC  0.68) were poorer discriminators. The optimal cut-off
tivity 0.838 and specificity 0.825. AUC  area under the curve; E  early dia-
I  left ventricular mass index; other abbreviations as in Figures 1 and 2.From
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y in th
EF and
 0.69
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ubjects, as previously reported (14,15,17,18). However,
ost of these changes were similarly observed in HLVH
ubjects, suggesting they were primarily related to coexisting
linical features. Between the 2 groups, LVH magnitude
nd atrial dilation/failure differed most, providing the best
eparation based on regression modeling and ROC analysis.
he results suggest that atrial function may be a key
ompensatory mechanism countering evolution of HFpEF,
nd they highlight the diagnostic utility of atrial failure as a
arker of the disease.
The term “heart failure with a preserved ejection fraction”
s descriptive of a syndrome involving multiple cardiovascu-
ar abnormalities that may each contribute to symptoms.
ascular and ventricular stiffening exacerbate blood pressure
uctuations, promote ventricular hypertrophic response,
ncrease cardiac systolic load particularly during stress, and
ompromise systolic reserve (18,38). Diastolic abnormalities
ead to higher filling pressures to achieve adequate filling,
ontributing to the redistribution of blood to the central
horax. Increased heart volume and exaggerated epicardial
onstraint may also contribute (18). Finally, atrial dilation
nd dysfunction likely represent loss of an important com-
ensation which becomes increasingly important given the
ther abnormalities. By comparing HFpEF with HLVH,
e were better able to resolve what may be the “last straw”
hat finally separates preclinical hypertensive heart disease
rom HFpEF. Our data do not refute results of earlier work
esigned to elucidate the pathophysiology of HFpEF (i.e.,
ontribution of individual factors). Rather, they show that
hen comparing preclinical HLVH with HFpEF, the
mount of concentric LV hypertrophy, LA remodeling, and
picardial volume enlargement are particularly abnormal.
The present results are in concert with earlier studies that
ompared HFpEF subjects with normotensive and/or non-
ypertrophied control subjects (1,9,13–18,20,39). However,
he fact that many similar abnormalities were observed in
ubjects with HLVH without HF makes it more difficult to
ssign primary causality to any one change. Advanced age,
ace, hypertension, gender, LVH, and obesity each signifi-
antly influences vascular and ventricular function
8,38,40,41), yet their presence does not guarantee HF
ymptoms. The present HFpEF patients were predomi-
antly African American, reflecting our inner-city referral
opulation, but this is an important group that often has
een overlooked. African Americans have a high prevalence
f hypertension and a higher propensity to develop LVH
7), display an earlier presentation of HFpEF (5), and may
ave a worse prognosis with this disease (42).
entricular function in HFpEF. Rest contractility ap-
eared normal in HFpEF, consistent with recent data (12),
lthough some systolic parameters were altered. Systolic
issue velocity was lower, as previously reported (43), but
as similarly reduced in HLVH, likely reflecting concentric
VH. Also as previously reported, HFpEF subjects had
reater end-systolic stiffening (Ees) than non-LVH control aubjects (18), yet this too was similarly observed in HLVH.
t remains unclear if contractility reserve is more limited in
FpEF, as some studies have suggested (44).
Both E/E= and IVRT differed between HFpEF and
LVH. As with the higher E/E=, a shorter IVRT could
eflect elevated diastolic pressures in HFpEF, although the
ack of correlation between variables may suggest another
echanism. Higher diastolic pressures can also be due to
ncreased LV filling (39), although this was not observed in
he present study, or to reduced chamber compliance (14),
lthough E-wave deceleration time, which estimates dia-
tolic compliance (45), was similar between HFpEF and
LVH groups. Another cause is exaggerated ventricular
nterdependence from pericardial constraint, which can
levate diastolic pressures even without diastolic ventricular
tiffening. This would be expected if total epicardial heart
olume increased (owing to atrial dilation and increased LV
ass), which we observed. In this setting, pericardial con-
ributions to intracavitary LV pressure become more appar-
nt, a finding supported by invasive analysis of the end-
iastolic pressure-volume relations in HFpEF (18).
pproximately 35% of resting LV diastolic pressure in
umans is attributable to external forces from right heart
nd pericardial loads (46). This does not imply pericardial
onstriction but rather a greater pericardial contribution to
easured LV diastolic pressures.
oncentric LVH, atrial enlargement, and dysfunction.
ncreased LA volumes are increasingly viewed as a marker
or diastolic dysfunction (33) and are an independent
redictor of coronary heart failure and worsened mortality
n previously asymptomatic elderly subjects with preserved
F (47). Atrial dilation occurs with age and can contribute
o alterations in LA pressure and therefore reduced early
iastolic filling (48). In the present study, age was similar
cross groups, yet further LA enlargement was observed in
FpEF. Although this could be explained by the greater
VH or higher diastolic pressures in this cohort, disparate
A size and function persisted after adjusting for these
arameters (Fig. 2). There may be disproportionate eleva-
ion of diastolic pressures during exercise in HFpEF com-
ared with HLVH subjects, which could underly chronic
trial dilation/dysfunction and/or the blunted A= response
uring handgrip. However, this remains speculative. Fur-
hermore, ventricles exposed to chronic pressure overload do
ot uniformly dilate or develop depressed function, and one
annot presume that all atria do either. The HFpEF
ubjects also had a greater prevalence of CAD, diabetes
49), impaired renal function, and obesity (50), and these
actors can favor volume retention and potentially contrib-
te to muscle damage in an overloaded atria.
The unique feature of atrial size (and function) was that
t was significantly altered only in HFpEF and, along with
VMI, provided the most sensitive and specific parameters
o differentiate HFpEF from HLVH subjects. The product
f the 2 does not convey a single physical property but serves
s a simple way to combine both findings in a diagnostic
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Pathophysiology of Heart Failure With Normal EF January 16, 2007:198–207ndex. This could also be done by a regression model. The
ack of specific easily employed diagnostic entry criteria has
een a barrier for clinical trials in HFpEF, and this index
ay be useful in this regard and further help identify
reclinical patients at higher risk to develop incident HF.
tudy limitations. Although we observed highly signifi-
ant differences for many parameters in HLVH and
FpEF versus control subjects, lack of differences between
he former 2 groups could relate to sample size (type II
rror). However, the fact that we observed marked differ-
nces in LV mass, atrial size, and function underscores the
obustness of the comparison. Furthermore, the sample size
as similar or greater than in most other detailed cardio-
ascular studies (12,14,15,18).
We used noninvasive measures of cardiovascular function,
nd although these have limitations and can yield values that
epend on the specific methods used (e.g., pulsed versus
olor-mode Doppler), differences between HFpEF and
ontrol subjects were compatible with earlier invasive data
12,14,18). We estimated PAWP by E/E=, which may be
ess accurate in subjects without LV dysfunction (32) but
as been found to be reliable in HFpEF (31). The HFpEF
roup was 76% African American, reflecting our urban
nner-city referral population. This may limit its applicabil-
ty to the broader population of HFpEF, because the degree
f ventricular remodeling is affected by race (7). Neverthe-
ess, many of the HFpEF results are similar to those
eported in a cohort that was 30% African American (5).
oronary artery disease was not directly assessed in most
ubjects, and its role in HFpEF potentially was overesti-
ated, because HLVH subjects were less often tested for
AD, and the incidence of oligosymptomatic CAD was
robably higher than their records or history conveyed (51).
inally, given the modest sample size, there is potential
nstability in the pooled statistical analysis, and some other
eatures might prove more discriminatory in a larger data set.
onclusions. Although multiple indexes of LV systolic,
iastolic, and vascular function are abnormal in HFpEF,
LVH subjects of similar age, gender, ethnicity without
F share many of these abnormalities. Quantitative differ-
nces in diastolic function exist between the groups, but
ith substantial overlap they appear difficult to use as a
obust distinguishing feature. The presence of more marked
oncentric hypertrophic remodeling of LV and left atrial
ysfunction/remodeling may provide more specific positive
iagnostic identifiers for HFpEF subjects and help assess
rognosis. The fact that these differences were present when
omparing HFpEF and HLVH suggests that excessive
VH, atrial dysfunction, and epicardial volume enlarge-
ent may represent important decompensations in the
athogenesis of HFpEF. It would be intriguing if reversal of
hese changes converted symptomatic HFpEF patients back
o more compensated HLVH subjects, but this remains to
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ersion of this article.
